Global Epidermolysis Bullosa Market Drivers
Increasing clinical trials for the treatment of epidermolysis bullosa is expected to propel the market growth over the forecast period.
For instance, on July 25, 2022, InMed Pharmaceuticals, Inc., which is involved in the research, development, manufacturing, and commercialization of rare cannabinoids INM-755 cannabinol cream for epidermolysis bullosa, provided an update that adolescent patients can participate in the clinical trial.
Moreover, on February 22, 2019, Phoenix Tissue Repair, Inc., a biotechnology company focused on developing a disease-modifying treatment for Dystrophic Epidermolysis Bullosa (DEB), announced that the first patient had been dosed in phase 1/2, first-in-human trial of PTR-01, a protein replacement therapy for recessive DEB.
Global Epidermolysis Bullosa Market Restraint
The high treatment cost of epidermolysis bullosa is expected to hinder the market growth over the forecast period.
For instance, according to the data published in the National Center for Biotechnology Information on September 8, 2020, the average monthly bandage cost epidermolysis bullosa range from US$ 262 to > US$ 2,000.
Epidermolysis Bullosa Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients